By Free Republic | Created at 2025-01-14 21:37:42 | Updated at 2025-01-18 07:48:16
3 days ago
Combination treatment for liver cancer significantly improves progression-free survival in global trial
Medical Xpress / The Mount Sinai Hospital / The Lancet ^ | Jan. 9, 2025
Posted on 01/14/2025 1:34:10 PM PST by ConservativeMind
Researchers at Mount Sinai have made a breakthrough in treating a type of liver cancer called hepatocellular carcinoma (HCC). This research tested a combination of treatments that could help patients live longer without their cancer getting worse.
Liver cancer is a serious and deadly cancer. In 2023, liver cancer was the fourth most common cause of death globally, accounting for more than 800,000 deaths annually. Hepatocellular carcinoma represents approximately 90% of primary liver cancers. This cancer is most commonly found in people living with chronic viral hepatitis, heavy alcohol use, or metabolic dysfunction-associated steatotic liver disease.
This landmark trial demonstrates that the novel combination of lenvatinib, pembrolizumab, and transarterial chemoembolization (TACE) significantly improves progression-free survival compared to TACE alone, addressing a critical unmet need in the treatment of intermediate-stage HCC.
"For over 20 years, TACE has been the standard treatment for intermediate-stage HCC, but its efficacy has been limited," said Dr. Llovet.
"Our study is the first to show a statistically significant improvement in progression-free survival when combining TACE with systemic therapies, paving the way for a potential new standard of care."
This combination therapy extended the time patients lived without disease progression compared to TACE alone. Additionally, a trend towards improved overall survival was observed, with longer follow-up planned to confirm these results.
"This approach represents a significant step forward in treating the 25% of liver cancer patients classified in the intermediate stage," said Dr. Llovet.
"For clinicians, this study introduces a groundbreaking approach to managing intermediate-stage HCC by integrating immunotherapy and targeted therapies with established local treatments. For patients, it offers hope for improved disease control and potentially extended survival compared to current standards."
(Excerpt) Read more at medicalxpress.com ...
TOPICS: Health/Medicine
KEYWORDS: lenvatinib; pembrolizumab; tace
Click here: to donate by Credit Card
Or here: to donate by PayPal
Or by mail to: Free Republic, LLC - PO Box 9771 - Fresno, CA 93794
Thank you very much and God bless you.
The important part:
“Lenvatinib, pembrolizumab, and transarterial chemoembolization (TACE) significantly improves progression-free survival compared to TACE alone.”
To: Mazey; ckilmer; goodnesswins; Jane Long; jy8z; ProtectOurFreedom; matthew fuller; telescope115; ...
The “Take Charge Of Your Health” Ping List
This high volume ping list is for health articles and studies which describe something you or your doctor, when informed, may be able to immediately implement for your benefit.
Email me to get on either the “Common/Top Issues” (20 - 25% fewer pings) or “Everything” list.
2 posted on 01/14/2025 1:35:05 PM PST by ConservativeMind (Trump: Befuddling Democrats, Republicans, and the Media for the benefit of the US and all mankind.)
Disclaimer: Opinions posted on Free Republic are those of the individual posters and do not necessarily represent the opinion of Free Republic or its management. All materials posted herein are protected by copyright law and the exemption for fair use of copyrighted works.
FreeRepublic.com is powered by software copyright 2000-2008 John Robinson
